DelveInsight’s “Metastatic Castration-Resistant Prostate Cancer Pipeline Insights 2026” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Metastatic Castration-Resistant Prostate Cancer pipeline landscape. It covers the Metastatic Castration-Resistant Prostate Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Metastatic Castration-Resistant Prostate Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download DelveInsight’s comprehensive Metastatic Castration-Resistant Prostate Cancer Pipeline Report @ https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-pipeline-insight

Key Takeaways from the Metastatic Castration-Resistant Prostate Cancer Pipeline Report

• On July 01, 2026, AstraZeneca initiated a phase III study is to demonstrate superiority of AZD2265 relative to standard of care treatments by assessment of radiographic progression-free survival (rPFS) and overall survival (OS) in participants with mCRPC. Approximately 670 adult participants with mCRPC will be randomized to receive either AZD2265 or standard of care treatment (investigator’s choice of cabazitaxel, ARPI switch, or radium-223). They will receive their assigned treatment until disease progression, unacceptable toxicity, or other discontinuation criteria are met. Tumor evaluation scans will continue after treatment discontinuation until radiographically confirmed progression or death.
• On July 01, 2026- Pfizer conducted a study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve. This is a global, multicenter, randomized Phase 3 study evaluating PF-06821497 (mevrometostat) in combination with enzalutamide versus placebo in combination with enzalutamide in participants with mCRPC where no systemic anti-cancer treatments have been initiated after documentation of mCRPC with the exception of ADT (androgen deprivation therapy) and first-generation anti-androgen agents.
• On July 01, 2026- Yale University announced a phase II study of bipolar androgen therapy (BAT) given in addition with standard of care Sipuleucel-T to determine the interferon (IFN) gamma Enzyme-linked Immunospot (ELISPOT) response rate to PA2024 (an engineered fusion protein of prostatic acid phosphatase and granulocyte-macrophage colony-stimulating factor which the activated autologous dendritic cells in the Sipuleucel-T vaccine are loaded with) in patients with metastatic castration resistant prostate cancer (mCRPC).
• DelveInsight’s Metastatic Castration-Resistant Prostate Cancer pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Metastatic Castration-Resistant Prostate Cancer treatment.
• The leading Metastatic Castration-Resistant Prostate Cancer Companies such as Surface Oncology, Regeneron Pharmaceuticals, Clovis Oncology, AstraZeneca, Veru Healthcare, Hinova Pharmaceuticals, Zenith Epigenetic, Eli Lilly and Company, Lantern Pharma, Astellas Pharma/Seagen, Pfizer, Progenics Pharmaceutical, Molecular Insight Pharmaceuticals, Bayer, Accutar Biotechnology Inc, Hinova Pharmaceuticals, Taiho Oncology, Inc., Forma Therapeutics, Inc., Dizal Pharmaceuticals, Amgen, and others.
• Promising Metastatic Castration-Resistant Prostate Cancer Therapies such as JNJ-78278343, Cetrelimab, Cabazitaxel, TVB-2640, Enzalutamide, Abiraterone acetate, JNJ-56021927, Xofigo (Radium-223 dichloride, BAY88-8223), and others.

Access DelveInsight’s in-depth MCRPC Pipeline Analysis for a closer look at promising breakthroughs @ Metastatic Castration-Resistant Prostate Cancer Clinical Trials and Studies

Metastatic Castration-Resistant Prostate Cancer Overview

Prostate cancer (PCa) is one of the most prevalent malignancies in the world and the third most common cause of male cancer-related death in the United States of America (USA). The majority of men with newly diagnosed PCa present with localized disease and undergo radical prostatectomy and/or radiological therapy, followed by androgen deprivation therapy (ADT). Depending on the grade of the cancer, a variable percentage of these patients experience progression to castration-resistant prostate cancer (CRPC) within 10 years. CRPC was previously named “hormone-refractory prostate cancer” and “androgen-independent prostate cancer”. However, because castration treatments including ADT were ineffective, these cancers still showed reliance upon hormones for androgen receptor (AR) activation.

Metastatic Castration-Resistant Prostate Cancer Emerging Drugs Profile

• SRF617: Surface Oncology

SRF617 is a fully human antibody designed to inhibit the enzymatic activity of CD39 in the tumor microenvironment, allowing for a dual mechanism of action to promote anti-tumor immunity via reduction of immunosuppressive adenosine in addition to increasing levels of immunostimulatory ATP. SRF617 has been granted Orphan Drug designation for the treatment of advanced pancreatic cancer by the FDA.

• Rucaparib: Clovis Oncology

Rucaparib is an oral, small molecule inhibitor of PARP1, PARP2 and PARP3 being developed in multiple tumor types, including ovarian and metastatic castration-resistant prostate cancers, as monotherapy, and in combination with other anti-cancer agents. Exploratory studies in other tumor types are also underway.

• HP518: Hinova Pharmaceuticals

HP518, a highly selective and orally bioavailable chimeric degrader targeting androgen receptor (AR) with the potential to overcome the drug resistance of prostate cancer due to some specific AR mutations. In discovery and preclinical studies, HP518 showed high degradation activity against wild type AR and some specific AR mutants that are resistant to enzalutamide, and excellent antitumor activity in xenograft mouse models. HP518 is highly selective for AR.

The Metastatic Castration-Resistant Prostate Cancer pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Castration-Resistant Prostate Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Castration-Resistant Prostate Cancer Treatment.
• Metastatic Castration-Resistant Prostate Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Metastatic Castration-Resistant Prostate Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Castration-Resistant Prostate Cancer market.

Explore DelveInsight’s expert-driven report today! @ Metastatic Castration-Resistant Prostate Cancer Unmet Needs

Metastatic Castration-Resistant Prostate Cancer Companies

Surface Oncology, Regeneron Pharmaceuticals, Clovis Oncology, AstraZeneca, Veru Healthcare, Hinova Pharmaceuticals, Zenith Epigenetic, Eli Lilly and Company, Lantern Pharma, Astellas Pharma/Seagen, Pfizer, Progenics Pharmaceutical, Molecular Insight Pharmaceuticals, Bayer, Accutar Biotechnology Inc, Hinova Pharmaceuticals, Taiho Oncology, Inc., Forma Therapeutics, Inc., Dizal Pharmaceuticals, Amgen, and others.

Metastatic Castration Resistant Prostate cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

• Oral
• Intravenous
• Subcutaneous

Metastatic Castration-Resistant Prostate Cancer Products have been categorized under various Molecule types such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Download DelveInsight’s latest report to gain strategic insights into upcoming MCRPC Therapies @ Metastatic Castration-Resistant Prostate Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the Metastatic Castration-Resistant Prostate Cancer Pipeline Report

• Coverage- Global
• Metastatic Castration-Resistant Prostate Cancer Companies- Surface Oncology, Regeneron Pharmaceuticals, Clovis Oncology, AstraZeneca, Veru Healthcare, Hinova Pharmaceuticals, Zenith Epigenetic, Eli Lilly and Company, Lantern Pharma, Astellas Pharma/Seagen, Pfizer, Progenics Pharmaceutical, Molecular Insight Pharmaceuticals, Bayer, Accutar Biotechnology Inc, Hinova Pharmaceuticals, Taiho Oncology, Inc., Forma Therapeutics, Inc., Dizal Pharmaceuticals, Amgen, and others.
• Metastatic Castration-Resistant Prostate Cancer Therapies- JNJ-78278343, Cetrelimab, Cabazitaxel, TVB-2640, Enzalutamide, Abiraterone acetate, JNJ-56021927, Xofigo (Radium-223 dichloride, BAY88-8223), and others.
• Metastatic Castration-Resistant Prostate Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Metastatic Castration-Resistant Prostate Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Find out in DelveInsight’s exclusive Metastatic Castration-Resistant Prostate Cancer Pipeline Report @ Metastatic Castration-Resistant Prostate Cancer Emerging Drugs and Major Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Metastatic Castration Resistant Prostate Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Metastatic Castration Resistant Prostate Cancer– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Rucaparib: Clovis Oncology
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Surface Oncology: SRF 617
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. REGN 4336: Regeneron Pharmaceuticals
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. HP 518: Hinova Pharmaceuticals
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Metastatic Castration Resistant Prostate cancer Key Companies
21. Metastatic Castration Resistant Prostate cancer Key Products
22. Metastatic Castration Resistant Prostate cancer- Unmet Needs
23. Metastatic Castration Resistant Prostate cancer- Market Drivers and Barriers
24. Metastatic Castration Resistant Prostate cancer- Future Perspectives and Conclusion
25. Metastatic Castration Resistant Prostate cancer Analyst Views
26. Metastatic Castration Resistant Prostate cancer Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/metastatic-castration-resistant-prostate-cancer-pipeline-insight